IRCT20221223056903N1 IRCT 2023-04-15 Sabzevar University of Medical Sciences Terazosin effect on the treatment of urinary tract obstruction symptoms in women Terazosin effect on the treatment of urinary tract obstruction symptoms in women 2023-02-20 anticipated 110 Complete https://irct.ir/trial/67574 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Urinary obstruction symptoms in women. Intervention group:A total of 110 people were randomly selected from those who referred to the Urology Clinic of Vasi Hospital and private practices with complaints of urinary obstruction symptoms and were included in the study after obtaining written informed consent. For all women referring with urinary obstruction symptoms,International scoring of symptoms prostate(IPSS) is completed first before treatment with terazosin. Then patients are subjected to uroflowmetry and determination of urinary residue. The drug terazosin is prescribed at a dose of 2 mg once a day for 1 month. Then the IPSS questionnaire is completed again by the patients, and uroflowmetry and urinary residual determination are performed for all patients.Then again the International scoring of symptoms prostate(IPSS) questionnaire by Takil patientsUroflowmetry and determination of urinary residue are performed for all patients. Since all participants are treated with the same drug and with the same dosage (i.e. terazosin 2 mg once a day for one month), there is no need toThe samples are not blinded.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information